A5044424550- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- vaccines and immunoinformatics approaches
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Urinary Bladder and Prostate Research
- Urologic and reproductive health conditions
- Cancer Research and Treatments
- Urological Disorders and Treatments
- Bone health and treatments
- Pediatric Urology and Nephrology Studies
- Complementary and Alternative Medicine Studies
- Cancer, Lipids, and Metabolism
- RNA Interference and Gene Delivery
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Immune Response and Inflammation
- Sarcoma Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Hormonal and reproductive studies
- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
Kurume University
2011-2020
Showa University
2020
Innovative Clinical Research
2012
National Institute of Technology, Sasebo College
1982-2012
Kitasato University
2010
Okayama University
2009
Kindai University
2009
Kurume University Medical Center
2008
Neurology, Inc
2004
Stanford University
2000-2003
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jul 2001RELATIONSHIP BETWEEN SYSTEMATIC BIOPSIES AND HISTOLOGICAL FEATURES OF 222 RADICAL PROSTATECTOMY SPECIMENS: LACK PREDICTION TUMOR SIGNIFICANCE FOR MEN WITH NONPALPABLE PROSTATE CANCER MASANORI NOGUCHI, THOMAS A. STAMEY, JOHN E. McNEAL, and CHERYL M. YEMOTO NOGUCHIMASANORI NOGUCHI , STAMEYTHOMAS STAMEY McNEALJOHN McNEAL YEMOTOCHERYL View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)66086-7AboutFull TextPDF...
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Aug 2003Prognostic Factors for Multifocal Prostate Cancer in Radical Prostatectomy Specimens: Lack Significance Secondary Cancers MASANORI NOGUCHI, THOMAS A. STAMEY, JOHN E. McNEAL, and ROSALIE NOLLEY NOGUCHIMASANORI NOGUCHI , STAMEYTHOMAS STAMEY McNEALJOHN McNEAL NOLLEYROSALIE View All Author Informationhttps://doi.org/10.1097/01.ju.0000070928.49986.04AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack...
To improve our understanding of transition zone cancer in terms the diagnosis and biological behavior we examined all morphological clinical variables 148 consecutive cases untreated after radical retropubic prostatectomy. We matched 79 by total volume to pure peripheral with no secondary tumors.Using Stanford technique prospective 3 mm. step sections identified 175 996 men (18%) prostatectomy who had largest zone. excluded 27 patients from study due previous transurethral prostatic...
Cancer stem cells (CSC) or cancer cell-like (CSC-LCs) have been identified in many malignant tumors. CSCs are proposed to be related with drug resistance, tumor recurrence, and metastasis considered as a new target for treatment; however, there only few reports on CSC-LCs renal cell carcinoma (RCC). Different approaches reported CSC identification, but no universal markers CSC. We used two different approaches, the traditional side population (SP) approach, enzymatic (aldehyde dehydrogenase...
Abstract Purpose: The aim of this study is to find a laboratory marker for overall survival in advanced cancer patients who were vaccinated with peptides based on pre-existing, peptide-specific CTL precursors the circulation. Experimental Design: A group 113 (28 colorectal, 22 prostate, 15 lung, 14 gastric, and 34 other cancers) was enrolled Phase I clinical peptide vaccination which prevaccination peripheral blood mononuclear cells measured, followed by these (maximum four). For cellular...
To assess the safety and immune response of a peptide-based immunotherapy for patients with hormone-refractory prostate cancer, phase I clinical trial was conducted.This study first investigated whether cytotoxic T-lymphocyte (CTL) precursors reacting to peptide vaccine candidates (14 peptides HLA-A24 positive patients) were detectable in pre-vaccination peripheral blood mononuclear cells (PBMCs) ten cancer. Patients then vaccinated subcutaneously only those which PBMCs reacted (CTL...
The prognosis of platinum-based chemotherapy-resistant metastatic urothelial cancer the bladder remains poor. Personalized selection right peptides for each patient could be a novel approach vaccine to boost anticancer immunity.In this randomized, open-label, phase II study, patients ages ≥18 years with progressive after first-line chemotherapy were randomly assigned (1:1) receive personalized peptide vaccination (PPV) plus best supportive care (BSC) or BSC. PPV treatment used maximum four...
The authors have shown that the primary determinants of prostate carcinoma progression are tumor volume and percent comprised Gleason Grade 4/5 cells. In current study evaluated six different techniques for morphometric measurements volume.A computer-assisted image analysis (NIH Image, developed maintained by National Institutes Health, Bethesda, MD) was used to analyze all 108 step-sectioned specimens obtained between January 1 December 31, 1997. Stanford technique 0.3-cm step-sections,...
To investigate immunological biomarkers to predict overall survival of advanced cancer patients under treatment with personalized peptide vaccination, correlations between and biomarkers, including cytotoxic T lymphocyte (CTL) immunoglobulin G (IgG) responses the vaccinated peptides, were investigated in 500 who received vaccination from October 2000 2008. The best clinical response was assessed for 436 patients, 43 (10%) had partial response, 144 (33%) stable disease 249 (57%) progressive,...
Abstract BACKGROUND Docetaxel‐based chemotherapy (DBC) showed limited clinical efficacy for castration‐resistant prostate cancer (CRPC) patients. To explore vaccine as a new treatment modality, we conducted phase II study of personalized peptide (PPV) DBC‐resistant CRPC METHODS Twenty patients and 22 with no prior DBC, control, were treated PPV using peptides chosen from 31 in patients, respectively. Cytokines, inflammatory markers, immune responses measured candidate biomarkers. without was...
BACKGROUND The safety, toxicity, and immunological response of individualized peptide vaccination or human leukocyte antigen (HLA)-A24+ hormone refractory prostate cancer (HRPC) patients in combination with a low dose estramustine were evaluated. METHODS Sixteen HLA-A24+ HRPC enrolled the phase I/II study. Conducted immune monitorings for those peptide-specific cytotoxic T lymphocyte (CTL) precursor analysis by interferon-γ production peptide-reactive immunoglobulin G (IgG) an enzyme-linked...
To evaluate, in a prospective, single-blind, randomized trial, the safety and efficacy of suspension technique for improving early recovery continence after radical retropubic prostatectomy (RRP).We randomly assigned 60 men with clinically localized prostate cancer to RRP; 30 were treated remaining not. All patients had RRP by same surgeon followed catheter removal on third day RRP. The primary outcome measures interval continence, positive margin rates. status was evaluated party using...
Abstract BACKGROUND The purpose of this study was to determine the safety and immune responses pre‐operative personalized peptide vaccine for patients with localized prostate cancer. METHOD Ten human leukocyte antigen (HLA)‐A24 + cancer received weekly six times positive peptides (up four kinds peptides) from 16 candidates, followed by a retropubic radical prostatectomy (RRP). Eight receiving RRP served as control group. serum prostate‐specific (PSA) level, peptide‐specific cytotoxic T...
Abstract BACKGROUND To evaluate the safety, tolerability, immune response, and antitumor activity of a combination personalized peptide vaccination (PPV) estramustine phosphate (EMP) in patients with castration‐resistant prostate cancer (CRPC). METHODS In phase I dose‐escalation study, four peptides showing highest levels peptide‐specific immunoglobulin G (IgG) to 14 vaccine candidates (ITK‐1) were subcutaneously injected every week three different dose settings (1, 3, 5 mg per peptide) for...
Since both tumor cells and immune cell repertoires are diverse heterogeneous, responses against tumor-associated antigens might be substantially different among individual patients. Personalized selection of right peptides for individuals could thus an appropriate strategy cancer vaccines. We have developed a novel immunotherapeutic approach, personalized peptide vaccination (PPV), in which HLA-matched selected administered, based on the pre-existing host immunity before vaccination. Recent...